Moss-FH for patients suffering
from aHUS Disease

Moss-FH is a recombinant protein in development as a treatment for atypical Haemolytic Uremic Syndrome (aHUS). The structure is closely aligned with human factor H, a regulator of complement activation.

Moss-FH compensates FH deficiency in mice

Moss-FH is designed to replace the missing or reduced activity of human regulator factor H in patients with aHUS, a rare, life-threatening genetic disease that damages vital organs such as kidney, heart and brain. Substitution of the mutant human regulator factor H with moss-FH has the potential for substantial improvements of patients’ quality of life in routine clinical care.

Preclinical trials show treatment with moss-FH reduces C3 deposits in mice kidney

Measurement of C3 deposition in untreated and moss-FH-treated diseased mice, and healthy controls
Measurement of C3 deposition in untreated and moss-FH-treated diseased mice, and healthy controls